Europe Infectious Disease Molecular Diagnostics Market Size - Share Outlook, Growth Analysis Report and Forecast Trends (2026-2035)

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Europe Infectious Disease Molecular Diagnostics Market Overview

Infectious disease molecular diagnostics continue to transform clinical testing by enabling faster, highly sensitive, and accurate detection of pathogens, supporting timely treatment decisions, improved disease surveillance, and effective infection control across diverse healthcare settings. The infectious disease molecular diagnostics market in Europe is poised to grow at a CAGR of 2.80% during the forecast period of 2026-2035. Market growth is driven by the rising burden of infectious diseases, increasing adoption of advanced molecular testing technologies, expanding diagnostic infrastructure, supportive healthcare initiatives, and growing demand for rapid, reliable, and precise diagnostic solutions across the region.

Europe Infectious Disease Molecular Diagnostics Market Growth Analysis and Key Influencers

Europe Infectious Disease Molecular Diagnostics Market Dynamics

The following section outlines the key factors influencing the growth of the market, including major drivers, restraints, and emerging opportunities.

Europe Infectious Disease Molecular Diagnostics Market Growth Drivers

Expansion of PCR Infrastructure to Strengthen Market Value

The expansion of polymerase chain reaction (PCR) laboratory infrastructure is accelerating the market by improving early disease detection, surveillance, and outbreak preparedness across Europe. According to the World Health Organization (WHO), a new PCR laboratory established in Plovdiv, Bulgaria, significantly expanded molecular diagnostic capacity for infectious diseases, including influenza, tuberculosis, COVID-19, HIV, and hepatitis, while strengthening regional surveillance and response capabilities. This continued investment in advanced molecular diagnostic infrastructure is expected to enhance testing capacity and support the long-term growth of the market.

Europe Infectious Disease Molecular Diagnostics Market Restraints

High Cost of Advanced Molecular Diagnostic Systems Limits the Market Growth

The high cost of advanced molecular diagnostic instruments, specialized reagents, and laboratory infrastructure continues to limit the market, particularly among smaller healthcare facilities and resource-constrained laboratories. In addition, ongoing maintenance requirements, workforce training, and operational expenses increase the overall cost of implementation, slowing the adoption of advanced infectious disease molecular diagnostic technologies and restricting broader market expansion across several European healthcare settings.

Europe Infectious Disease Molecular Diagnostics Market Opportunities

Advancements in PCR-Based Solutions Create New Avenues for the Market Landscape

Continuous innovation in PCR-based molecular diagnostics is creating significant potential for the market by improving the speed, accuracy, and scope of infectious disease detection. For instance, in May 2026, Seegene launched the Allplex MDRO Assay in Europe, a real-time multiplex PCR solution designed for rapid detection of multidrug-resistant organisms and resistance genes to strengthen hospital infection control. Such product innovations are expected to expand clinical applications and support the sustained growth of the market.

Europe Infectious Disease Molecular Diagnostics Market Trends

The market is witnessing several trends, including PCR innovation, decentralized testing, and collaborative diagnostic development.

Growing Collaborative Development of Advanced Molecular Diagnostics is Boosting the Market Value

Strategic collaboration to accelerate the development of next-generation molecular diagnostic technologies is emerging as a key trend in the market. For example, in June 2026, a new pan-European diagnostics network was launched to support the development of innovative infectious disease diagnostic tools across Europe. Such collaborative research initiatives are expected to accelerate technological advancement and strengthen the long-term growth of the market.

Europe Infectious Disease Molecular Diagnostics Market Share

Polymerase Chain Reaction Segment by Technology is Expected to Lead the Market

The market is segmented by technology into polymerase chain reaction (PCR), isothermal nucleic acid amplification technology, DNA Sequencing and next generation sequencing, in situ hybridization, DNA microarrays, and others. Among these, polymerase chain reaction is expected to dominate due to its high accuracy, rapid turnaround time, and broad application in infectious disease diagnosis. For example, in May 2026, bioMérieux announced an investment of more than EURO 250 million to establish a new manufacturing facility in France dedicated to BIOFIRE® PCR tests for the European market. This investment is expected to strengthen PCR production capacity and reinforce the market.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Europe Infectious Disease Molecular Diagnostics Market Analysis by Region

The regions included in the report include Germany, the United Kingdom, France, Italy, Spain, Russia, the Netherlands, Switzerland, Belgium, and the Rest of Europe. Among these, Germany is expected to lead the market owing to its strong diagnostics ecosystem, growing innovation, and increasing investments in molecular diagnostic technologies. For instance, in June 2026, Germany-based Intu Diagnostics secured EURO 1.1 million to advance its lab-free molecular diagnostics platform for infectious disease testing and prepare for large-scale commercialization. Such investments are expected to strengthen innovation and support the continued expansion of the market.

Leading Players in the Europe Infectious Disease Molecular Diagnostics Market

Europe Infectious Disease Molecular Diagnostics Market Segmentation

Key Questions Answered in the Europe Infectious Disease Molecular Diagnostics Market Report

• What was the Europe infectious disease molecular diagnostics market value in 2025?
• What is the Europe infectious disease molecular diagnostics market forecast outlook for 2026-2035?
• What are the major factors aiding the Europe infectious disease molecular diagnostics market demand?
• How has the market performed so far, and how is it anticipated to perform in the coming years?
• What are the market's major drivers, opportunities, and restraints?
• What are the major European infectious disease molecular diagnostics market trends?
• Which products and services are expected to dominate the market segment?
• Which type is projected to lead the market segment?
• Which test type is anticipated to drive the market segment?
• Which disease type is likely to dominate the market segment?
• Which technology is expected to dominate the market segment?
• Which end user is projected to lead the market segment?
• Who are the key players involved in the Europe infectious disease molecular diagnostics market?
• What are the current unmet needs and challenges in the market?
• How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?

Research Methodology

This report is developed through a robust mixed-methods research design combining:

• Primary Research: In-depth interviews conducted with 30+ molecular diagnostics specialists, clinical microbiologists, infectious disease physicians, laboratory directors, hospital procurement managers, and diagnostic industry executives across major European countries, including key opinion leaders (KOLs) from leading hospitals, reference laboratories, and public health institutions.
• Secondary Research: Peer-reviewed publications from The Lancet Infectious Diseases, Clinical Microbiology and Infection, and Journal of Clinical Microbiology; data from the World Health Organization (WHO), European Centre for Disease Prevention and Control (ECDC), European Commission, ClinicalTrials.gov, company annual reports, investor presentations, product portfolios, regulatory filings, press releases, and official company websites of leading molecular diagnostics manufacturers.
• Validation: All market estimates and forecasts are validated through top-down and bottom-up market sizing, data triangulation, cross-verification with secondary sources, and iterative expert review to ensure accuracy and consistency.